Browse > Article

Investigation Synergism of Eunkyo-san, a Poly-herbal Formula and Ciprofloxacin against Streptococcus pneumoniae Respiratory Infection  

Lee, Sang-Jun (Division of Respiratory System, College of Oriental Medicine, Daegu Haany University)
Jeon, Kwi-Ok (Division of Respiratory System, College of Oriental Medicine, Daegu Haany University)
Song, Kwang-Kyu (Division of Respiratory System, College of Oriental Medicine, Daegu Haany University)
Choi, Hae-Yun (Division of Respiratory System, College of Oriental Medicine, Daegu Haany University)
Kim, Jong-Dae (Division of Respiratory System, College of Oriental Medicine, Daegu Haany University)
Publication Information
Journal of Physiology & Pathology in Korean Medicine / v.19, no.4, 2005 , pp. 1039-1045 More about this Journal
Abstract
In order to evaluate the in vivo synergic effect of Eunkyo-san which was a traditional poly-herbal formula has been used in the treatment of respiratory diseases in Korea, with quinolone antibiotics, ciprofloxacin (CPFX), the viable bacterial number and histopathological changes were monitored after experimental respiratory infection with S. pneumoniae ATCC 6303. The obtained results were as follows: In CPFX groups, the viable bacterial numbers were significantly decreased compared to that of control group and these were more dramatically decreased compared to that of single treatment with CPFX, respectively in concomitant treated groups with Eunkyo-san. In control group, severe infiltration of inflammatory cells, hemorrhage and hypertrophy of alveolar linings were demonstrated at microscopical levels. However, these abnormal histopathological changes were significantly decreased compared to that of control group in CPFX groups, and these were more dramatically decreased compared to that of single treatment with CPFX, respectively in concomitant treated groups with Eunkyo-san. In CPFX groups, the LSA (luminal surface of alveoli $\%$) were significantly increased compared to that of control group and these were more dramatically decreased compared to that of single treatment with CPFX, respectively in concomitant treated groups with Eunkyo-san. According to these results, it is considered as the in vivo antibacterial activity of CPFX was dramatically increased by concomitant use of Eunkyo-san against S. pneumoniae ATCC 6303 infection of respiratory tract.
Keywords
Eunkyo-san; quinolone; Ciprofloxacin(CPFX); S. pneumoniae; infection of respiratory tract.;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Gordon, R.C. Community-acquired pneumonia in adolescents. Adolesc Med 11(3):681-695, 2000.
2 Farker, K., Naber, K.G., Funfstuck, R Fluoroquinolones: utilization in renal and urogenital tract infections. Med Klin 96, 383-390, 2001.
3 Ho, K.Y., Tsai, C.C., Chen, C.P., Huang, J.S., Lin, C.C Antimicrobial activity of honokiol and magnolol isolated from Magnolia officinalis. Phytother Res 15(2):139-141, 2001.
4 Mahasneh, A.M., El-Oqlah, A.A. Antimicrobial activity of extracts of herbal plants used in the traditional medicine of Jordan. J Ethnopharmacol 64(3):271-276, 1999.
5 김상찬, 김선희외 9명. 방제학. 영림사, 서울, p 83-84, 1999.
6 Berry, V., Page, R., Satterfield, J., Singley, C., Straub, R., Woodnutt, G. Comparative in vivo activity of gemifloxacin in a rat model of respiratory tract infection. J Antimicrob Chemother 45, 79-85, 2000.
7 Mattie, H., Hoogeterp, J.J., Terporten, P. The activity of ciprofloxacin against Pseudomonas aeruginosa in normal and granulocytopenic mice. Pharm Weekbl Sci 11, 526-529, 1987.
8 Roosendaal, R., Bakker-Woundenberg, I.A., van den Berghe-van Raffe M., Vink-van den Berg, J.C, Michel, M.F. Comparative activities of ciprofloxacin and ceftazidime against Klensiella pneumoniae in vitro and in experimental pneumonia in leukopenic rats. Antimicrob Agents Chemother 31(11):1809-1815, 1987.
9 File, T.M. The epidemiology of respiratory tract infections. Semin Respir Infect 15(3):184-294, 2000.
10 Stahlmann, R, Lode, H. Toxicity of quinolones. Drugs 58, 37-42, 1999.
11 Lopez, A., Hudson, J.B., Towers, G.H. Antiviral and antimicrobial activities of Colombian medicinal plants. J Ethnopharmacol 77(2):189-196, 2001.
12 Cosentini, R, Blasi, F. New pathogens for respiratory infections. Curr Opin Pulm Med 2(3):174-180, 1996.
13 Ball, P. Quinolone generations: natural history or natural selection? J Antimicrob Chemother 46, 17-24, 2000.
14 Janoir, C. Varon, E., Kitzis, M.D., Gutmann, L. New mutation in parE in a pneumococcal in vitro mutant resistant to fluoroquinolones. Antimicrob Agents Chemother 45(3):952-955, 2001.
15 Bergan, T. Extravascular penetration of ciprofloxacin. A review Diagn Microbiol Infect Dis 13, 103-114, 1990.
16 Elgayyar, M., Draughon, F.A., Golden, D.A., Mount, J.R. Antimicrobial activity of essential oils from plants against selected pathogenic and saprophytic microorganisms. J Food Prot 64(7):1019-1024, 2001.
17 Weller, T.M., Andrews, J.M., [evens, G., Wise, R The in vitro activity of BM-284756, a new des-fluorinated quinolone. J Antimicrob Chemother 49(1):177-184, 2002.
18 Martinez, F.F., Carabias, M.L., Izquierdo, J.I., Centelles, M.L., Prieto, J.P. Comparison of the in vitro and in vivo effects of meropenem and ciprofloxacin on the morphology of Escherichia coli and Staphylococcus aureus. Rev Esp Quimioter 11(3):238-244, 1998.
19 Nau, R., Schmidt, T., Kaye, K., Froula, J.L., Tauber, M.G. Quinolone antibiotics in therapy of experimental pneumococcal meningitis in rabbits. Antimicrob Agents Chemother 39(3):593-597, 1995.
20 全國韓醫科大學肺系內科學敎室編著. 東醫肺系內科學. p.85, 98, 140, 263, 282, 311, 한문화사, 서울, 2002.
21 Gillespie, S.H., Morrissey, I., Everett, D. A comparison of the bactericidal activity of quinolone antibiotics in a Mycobacterium fortuitum model. J Med Microbiol 50(6): 565-570, 2001.
22 Kim, C.M., Heo, M.Y., Kim, H.P., Shin, K.S., Pachaly P. Pharmacological activities of water extracts of Umbelliferae plants. Arch Pharm Res 14, 87-92, 1991.
23 Roos, K.L. Acute bacterial meningitis. Semin Neurol 20(3): 293-306, 2000.
24 McGee, L., Goldsmith, C.E., Klugman, K.P. Fluoroquinolone resistance among clinical isolates of Streptococcus pneumoniae belonging to international multiresistant clones. J Antinicrob Chemother. 49(1):173-176, 2002.
25 Fitzgibbon, J.E., Nahvi, M.D., Dubin, D.T., John, J.F. Jr. A sequence variant of Staphylococcus hominis with a high prevalence of oxacillin and fluoroquinolone resistance. Res Microbiol 152(9):805-810, 2001.
26 韓鏞微. 임상호흡기학. 一朝閣, 서울, p 139, 146, 47-81, 1997.
27 楊進 編. 溫病條辦. 中國醫藥科技出版社, 北京, 1996.
28 Bachoual, R., Ouabdesselam, S., Mory, F., Lascols, C., Soussy, C.J., Tankovic, J. Single or double mutational alterations of gyrA associated with fluoroquinolone resistance in Campylobacter jejuni and Campylobacter coli.Microb Drug Resist 7(3):257-261, 2001.
29 Cunha, B.A Antibiotic resistance. Med Clin North Am 84(6):1407-1429, 2000.
30 Ojala, T., Remes, S., Haansuu, P., Vuorela, H., Hiltunen, R., Haahtela, K., Vuorela, P. Antimicrobial activity of some coumarin containing herbal plants growing in Finland. J Ethnopharmacol 73(1-2):299-305, 2000.
31 Joyanes. P., Pascual, A., Gimenez, M.J., Garcia, I., Aguilar, L., Perea, E. Differences between two new quinolones (gemifloxacin and trovafloxacin) and ciprofloxacin in their concentration-dependent killing of Streptococcus pneumoniae. Chemotheraphy 47(6):409-414, 2001.
32 Moreillon, P., Wengner, A, Caldelari, I. Pneumococcal antibiotic resistance. Rev Med Suisse Romande 120, 651-659, 2000.
33 Ball, P. Future of the quinolones. Semin Respir Infect 16(3): 215-224, 2001.
34 Hakanen, A., Kotilainen, P., Huovinen, P., Helenius, H., Siitonen, A Reduced fluoroquinolone susceptibility in Salmonella enterica serotypes in travelers returning from Southeast Asia. Emerg Infect Dis 7(6):996-1003, 2001.
35 Satoh, K, Sakagami, H., Ida, Y., Komatsu, N., Fujimaki, M., Nakashima, H., Kanbara, K, Gupta, M., Sarma, D.N., Mitra, S.K. Antimicrobial and radical modulation activity of AV-07, a poly-herbal formula. In Vivo 14(2):351-355, 2000.
36 Desta, B. Ethiopian traditional herbal drugs. Part II: Antimicrobial activity of 63 medicinal plants. Ethnopharmacol 39(2):129-139, 1993.
37 Rubinstein, E. History of quinolones and their side effects. Chemotherapy 47, 3-8, 2001.
38 Van Puyvelde, L., Geiser, I., Rwangabo, P.C, Sebikali, B. Rwandese herbal remedies used against gonorrhoea. J Ethnopharmacol 8(3):279-286, 1983.
39 Onyeji, C.O., BUi, K.Q., Owens, R.C. Jr, Nicolau, D.P., Quintiliani, R., Nightingale, C.H. Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia. Int J Antirnicrob Agents 12(2):107-114, 1999.
40 Givner, L.B., Mason, E.O. Jr, Barson, W.J., Tan, T.Q., Wald, E.R, Schutze, G.E., Kim, KS., Bradley, J.5., Yogev, R, Kaplan, S.L. Pneumococcal facial cellulitis in children. Pediatrics 106(5), E61, 2000.
41 Appelbaum, P.C., Hunter, P.A. The fluoroquinolone antibacterials : past, present and future perspectives. Int J Antimicrob Agents 16(1):5-15, 2000.
42 Paladino, J.A. Is more than one quinolone needed in clinical practice? Ann Pharmacother 35(9):1085-1095, 2001.
43 Lin, R., Holland, G.N., Helm, C.J., Elias, S.J., Berlin, O.G., Bruckner, D.A. Comparative efficacy of topical ciprofloxacin for treating Mycobacterium fortuitum and Mycobacterium chelonae keratitis in an animal model. Am J Ophthalmol 117(5):657-662, 1994.
44 Ruiz, J., Sierra, J.M., De Anta, M.T., Vila, J. Characterization of sparfloxacin-resistant mutants of Staphylococcus aureus obtained in vitro. Int J Antimicrob Agents 18(2):107-112, 2001.